View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 29, 2020

University of Queensland reports positive findings on Covid-19 vaccine

The University of Queensland (UQ) in Australia has reported positive findings from early preclinical testing of its Covid-19 vaccine candidate.

The University of Queensland in Australia has reported positive findings from early preclinical testing of its Covid-19 vaccine candidate.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

According to the data, the vaccine candidate raised significant levels of antibodies to neutralise the virus.

The University of Queensland received funding and support from the Coalition for Epidemic Preparedness Innovation (CEPI) to develop a Covid-19 vaccine.

The university collaborated with the Peter Doherty Institute for Infection and Immunity to study the vaccine and its immune response.

University of Melbourne professor Kanta Subbarao, part of the Doherty Institute, analysed samples provided by the UQ team.

The preclinical analysis revealed high levels of antibodies that could neutralise infection by the live virus in cell culture, noted UQ.

University of Queensland project co-leader professor Paul Young said: “This is what we were hoping for, and it’s a great relief for the team given the tremendous faith placed in our technology by CEPI, Federal and Queensland Governments and our philanthropic partners.

“We were particularly pleased that the strength of the antibody response was even better than those observed in samples from Covid-19 recovered patients.”

These findings are considered important as similar immune responses in animal models administered with SARS vaccines were observed to result in protection from infection.

The University of Queensland is also working with Viroclinics Xplore in the Netherlands to expedite the vaccine’s development.

The University of Queensland team had prioritised obtaining robust pre-clinical and safety data before advancing the vaccine to human clinical trials.

Joint University of Queensland project leader Dr Keith Chappell noted: “Viroclinics Xplore is investigating in more detail the vaccine’s ability to protect from direct challenge by the live virus in multiple animal models, and without this partnership, this just wouldn’t have been possible in this time frame with the capabilities we have here in Australia.”

Recently, the University of Queensland partnered with Cytiva for manufacturing activities, while discussions are ongoing with other commercial firms.

Other partners for the project include Lonza, Thermo Fisher Scientific, Syneos Health and the CSIRO, CSL/Seqirus, Dynavax and GlaxoSmithKline (GSK).

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology